Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

  • This share is currently suspended. It was suspended at a price of 6.75
  • There is currently no data for DCTA

New Safety Test

19 Apr 2021 07:00

RNS Number : 8065V
Directa Plus PLC
19 April 2021
 

This is a Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

19 April 2021

 

Directa Plus plc

("Directa Plus" or the "Company")

 

New G+ Coating for Fabrics Dermatologically Tested

 

Human patch test results establish coating as suitable for skin contact

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company's new G+® graphene coating for fabrics has been tested by an independent third party laboratory and found to be suitable for human skin contact. Since 2014, Directa Plus has commissioned 28 tests on different morphologies of G+® graphene, all of which have certified the absence of any negative impacts on biological systems.

 

The latest test was a human patch test, using volunteers, to assesses any potential side effects (skin erythema and oedema reactions) that may occur after applying the G+® product and to evaluate whether the product is safe for consumer use. The results showed zero erythema and oedema reactions across all subjects participating in the test and the G+® coated fabric was reported to be 'dermatologically tested' and non-irritating.

 

The G+® coating has been developed specifically for the automotive, upholstery, interior design, accessories and consumer electronics markets. It is thermally and electrically conductive, antibacterial and antiviral (certified to be anti-sars cov-2), UV and abrasion-resistant and can be applied to a wide variety of substrates, from natural and artificial fabrics to non-woven and microfiber, as well as felt and leather.

 

Giulio Cesareo, Chief Executive of Directa Plus, commented: "As always, our products are tested to the highest possible standards before releasing them to our target markets. Because our products are dermatologically tested to be non-toxic and hypoallergenic, Directa's business partners can develop innovative new products knowing that they will be safe for their own consumers."

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

 

Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald / Pete Lynch

 

N+1 Singer (Joint Broker)

+44 20 7496 3069

Rick Thompson / Phil Davies

 

Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson / Edward Lee

 

 

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product), textiles (based on our G+ products) and more recently, lithium-sulphur batteries. In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.

 

-ends-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUWRBRAUUSAAR
Date   Source Headline
18th Oct 201911:36 amRNSResult of Open Offer, and GM, Issue of Equity
30th Sep 20192:21 pmRNSAcquisition, Placing and Open Offer
30th Sep 20192:21 pmRNSHalf-year Report
10th Sep 20197:00 amRNSNew Textile Membrane Patent Granted
6th Aug 20198:29 amRNSHolding(s) in Company
29th Jul 20197:00 amRNSAward of Oil Decontamination and Recovery Contract
22nd Jul 20197:00 amRNSHolding(s) in Company
4th Jul 20197:00 amRNSUS Patent Grant for Liquid G+
27th Jun 20197:00 amRNSGrant of US Patent
26th Jun 20199:47 amRNSHolding(s) in Company
18th Jun 20191:36 pmRNSResult of AGM
18th Jun 20197:00 amRNSAGM Statement
17th Jun 20197:00 amRNSHolding(s) in Company
28th May 20197:00 amRNSDirector/PDMR Shareholding
23rd May 20197:00 amRNSNew patent grants
23rd May 20197:00 amRNSPosting of Annual Report and Notice of AGM
7th May 20197:00 amRNSCo-operation agreement with Alfredo Grassi S.p.A.
17th Apr 20197:00 amRNSFinal Results for the Year to 31 December 2018
1st Apr 20197:00 amRNSSuccessful First Road Surface Trial Results
4th Mar 20197:00 amRNS3 Year Exclusive Agreement with Loro Piana
6th Feb 20197:00 amRNSUS National Graphene Association Appointment
31st Jan 20194:41 pmRNSHolding(s) in Company
31st Jan 20199:05 amRNSSecond Price Monitoring Extn
31st Jan 20199:00 amRNSPrice Monitoring Extension
30th Jan 20193:45 pmRNSHolding(s) in Company
30th Jan 201911:00 amRNSHolding(s) in Company
30th Jan 201911:00 amRNSHolding(s) in Company
30th Jan 201911:00 amRNSHolding(s) in Company
8th Jan 201911:58 amRNSResult of General Meeting and Total Voting Rights
7th Jan 20191:00 pmRNSResults of Open Offer
13th Dec 20187:00 amRNSAnnouncement of Open Offer
12th Dec 20183:30 pmRNSResults of Placing
12th Dec 201811:30 amRNSProposed Placing to raise a minimum of £3 million
5th Dec 20187:00 amRNSDirecta Plus to present at Denim Première Vision
29th Nov 20187:00 amRNSCollaboration Agreement with Ambienthesis S.p.A.
23rd Nov 20184:00 pmRNSDirecta Plus to present at Mello London
23rd Nov 20187:00 amRNSEnvironmental Sale and Participation in Trial
22nd Nov 20187:00 amRNSTrading Update
30th Oct 20189:15 amRNSFurther Agreement with Arvind, Launch of G+ Jeans
23rd Oct 20187:00 amRNSSignificant Textiles Order
28th Sep 201812:55 pmRNSDirector/PDMR Shareholding
26th Sep 20182:24 pmRNSReplacement: Director/PDMR Shareholding
26th Sep 201812:52 pmRNSDirector/PDMR Shareholding
26th Sep 20187:00 amRNSWorld's First Road Surface Containing Graphene
25th Sep 20187:00 amRNSHalf-year Report
31st Jul 20187:00 amRNSAppointment of N+1 Singer as Joint Broker
9th Jul 201810:00 amRNSOakley and Bioracer launch Graphene Plus jersey
4th Jul 20187:00 amRNSSecond significant order from Alfredo Grassi
18th Jun 20184:28 pmRNSResult of AGM
18th Jun 20187:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.